Overview
Hepatocellular carcinoma (HCC) with a scirrhous phenotype represents a challenging subset of advanced liver malignancies characterized by dense fibrous tissue deposition within the tumor. This clinical entity often presents with complex features including tumor thrombi, multifocal disease, and aggressive biological behavior, contributing to a poor prognosis. Diagnostic approaches must be meticulous to accurately identify these tumors, while management strategies require a multidisciplinary approach tailored to individual patient factors such as tumor extent, underlying liver function, and systemic health. Emerging targeted therapies and advanced imaging techniques offer promising avenues for improving outcomes, particularly in patients ineligible for curative treatments like surgery or ablation.
Clinical Presentation
Patients with scirrhous HCC often present with a spectrum of clinical manifestations reflecting the advanced stage and multifocal nature of the disease. Tumor thrombi, observed in 10%–40% of locally advanced HCC cases, are particularly concerning as they significantly impact prognosis [PMID:28569169]. These thrombi can obstruct hepatic vasculature, leading to complications such as portal hypertension, ascites, and hepatic insufficiency. Additionally, the relapsing multifocal nature of HCC, as highlighted in a case report involving a 51-year-old female, underscores the heterogeneity and complexity of disease progression [PMID:35764068]. Multifocal disease complicates both diagnosis and treatment, necessitating comprehensive imaging and biomarker assessments to guide therapeutic decisions. Clinical symptoms may include nonspecific signs such as weight loss, abdominal pain, and jaundice, alongside more specific indicators like elevated α-fetoprotein (AFP) levels, which are crucial for monitoring disease activity and treatment response [PMID:35764068].
Diagnosis
Accurate diagnosis of scirrhous HCC is pivotal for effective management and involves a combination of imaging modalities and biomarker analysis. Contrast-enhanced computed tomography (CBCT) with both arterial and portal venous phases, achieved through a single contrast injection, has demonstrated diagnostic accuracy comparable to biphasic multi-detector CT (MDCT) [PMID:33761647]. The arterial phase helps in identifying hypervascular characteristics, while the portal venous phase, particularly noted for characteristic corona enhancement patterns, aids in distinguishing HCC from benign arterioportal shunts, thereby enhancing diagnostic specificity [PMID:33761647]. Magnetic resonance imaging (MRI), ultrasonography, and CT scans are integral in identifying tumor thrombi, providing critical information for staging and planning interventions [PMID:28569169]. Biomarker analysis, such as GPC3 (Glypican-3) expression, offers personalized treatment approaches, as evidenced by the efficacy of GPC3-targeted nanoplatforms in delivering therapeutic agents specifically to HCC cells, thereby minimizing systemic toxicity [PMID:42027106]. Monitoring AFP levels alongside imaging modalities like repeated CT scans remains essential for assessing treatment efficacy and disease progression [PMID:35764068].
Management
The management of scirrhous HCC requires a multifaceted approach tailored to the extent of disease and patient-specific factors. Conventional treatments such as transarterial chemoembolization (TACE) benefit from advanced imaging techniques like CBCT, which offer rapid acquisition and high-quality images crucial for precise planning and execution [PMID:33761647]. For patients unsuitable for surgical resection or ablation due to extensive tumor burden or underlying cirrhosis, TACE remains a cornerstone therapy. However, studies indicate that incorporating higher dose accurate radiotherapy (A-RT), including intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT), in conjunction with TACE can potentially improve survival outcomes compared to lower dose radiotherapy or TACE alone [PMID:28569169]. Targeted therapies, exemplified by the GPC3-specific nanoplatform (VRS@MLP-hGPC3), which delivers ferroptosis inducers and photothermal agents directly to HCC cells, show promise in enhancing local tumor control with reduced systemic toxicity [PMID:42027106]. Clinical case reports further support the efficacy of combined therapies like vascular-targeted photodynamic therapy (VAE) and locoregional locoregional therapy (LOLA), leading to significant tumor regression and sustained remission over extended periods [PMID:35764068]. Additionally, nonrigid image registration techniques significantly improve the accuracy of assessing ablation margins, particularly benefiting less experienced radiologists, thereby reducing the risk of local tumor progression (LTP) [PMID:28091728].
In preclinical settings, pharmacological interventions like celecoxib have shown potential in modifying the natural history of HCC by reducing tumor development and promoting benign nodule formation in animal models [PMID:23619259]. While these findings are promising, translating such insights into clinical practice requires further investigation to establish safety and efficacy in human subjects.
Prognosis & Follow-up
The prognosis for patients with scirrhous HCC is generally guarded, with tumor thrombi serving as significant prognostic factors negatively impacting overall survival [PMID:28569169]. However, advancements in combination therapies, particularly those integrating targeted delivery mechanisms and multimodal treatments, suggest potential improvements in patient outcomes. For instance, the synergistic effects of ferroptosis induction and photothermal ablation not only ablate tumor cells but also modulate the immune response and reduce metastatic potential [PMID:42027106]. Long-term follow-up data from case reports indicate sustained complete remission and improved quality of life over extended periods, highlighting the potential for durable responses with optimized treatment regimens [PMID:35764068]. Regular imaging and biomarker monitoring, including AFP levels and imaging assessments, are crucial for early detection of recurrence and guiding timely interventions [PMID:35764068]. The use of advanced imaging techniques, such as nonrigid registration, significantly reduces the risk of local tumor progression by accurately assessing treatment margins, thereby stratifying patients into low-risk and high-risk categories for LTP [PMID:28091728].
Key Recommendations
References
1 Higashihara H, Osuga K, Onishi H, Nakamoto A, Tsuboyama T, Tomiyama N. The diagnostic value of dual-phase cone-beam CT during hepatic arteriography in transarterial chemoembolization for hepatocellular carcinoma. Medicine 2021. link 2 Kong XQ, Dong YP, Wu JX, He JY, Le YY, Du KX et al.. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiation oncology (London, England) 2017. link 3 Li S, Wang Z, Zhou M, Jia W, Shi Z, Mao X et al.. Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma. ACS applied materials & interfaces 2026. link 4 Orange M, Poidimani N, Crosignani A, Werthmann PG, Bertotto C. Complete, Durable Remission of Advanced Hepatocellular Carcinoma under Treatment with Viscum album Extracts: A Case Report. Complementary medicine research 2022. link 5 Park J, Lee JM, Lee DH, Joo I, Yoon JH, Park JY et al.. Value of Nonrigid Registration of Pre-Procedure MR with Post-Procedure CT After Radiofrequency Ablation for Hepatocellular Carcinoma. Cardiovascular and interventional radiology 2017. link 6 Galant LW, de Mattos AA, Menti E, Valiatti FB, de Mattos AZ, Porawski M et al.. The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats. Annals of hepatology 2013. link